Antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial, which was in the first of usually three phases of clinical testing, the University of Oxford said in a statement.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/f8hmMik
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» AstraZeneca's COVID vaccine suffers a setback in nasal spray trial
https://ift.tt/1iITkuS
No comments:
Post a Comment